Trials / Completed
CompletedNCT03471741
Intensity Modulated Radiotherapy With Concomitant Boost in Breast Cancer
Moderated Accelerated RAdiotherapy (MARA-2) in Moderate-high Risk Breast Cancer: a Phase I-II Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 451 (actual)
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna · Academic / Other
- Sex
- Female
- Age
- —
- Healthy volunteers
- Not accepted
Summary
To assess feasibility of postoperative IMRT with concomitant boost in moderate-high risk breast cancer in terms of late toxicity and local control
Detailed description
Patients treated conservatively with moderate-high risk breast cancer were treated with IMRT plus concomitant boost to surgical bed (up to a dose of 50 Gy to whole breast and 60 Gy to the tumor bed). Aim of the study was to evaluate late toxicity and local control after this treatment compared with a historical control group (CG) of patients treated with 3D-conformal postoperative radiotherapy delivered with conventional fractionation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | IMRT with concomitant boost | |
| RADIATION | 3D-RT with sequential boost |
Timeline
- Start date
- 2001-06-01
- Primary completion
- 2017-12-31
- Completion
- 2017-12-31
- First posted
- 2018-03-21
- Last updated
- 2018-03-21
Source: ClinicalTrials.gov record NCT03471741. Inclusion in this directory is not an endorsement.